Terazosin (CED0005671)

Terazosin is an exogenous organic compound with the formula C19H25N5O4 and an average molecular weight of 387.43 g/mol. At room temperature, it exists as a solid. Terazosin belongs to the piperazines, a subclass of diazinanes within the organic compounds. The compound is recorded in 11 sources, including healthcare, pharmaceuticals, and veterinary products as a drug used in benign prostatic hypertrophy; food, food processing, and cookware for food preservation; household cleaning and consumer products such as tobacco smoke filters, cigar cigarettes, non-electric simulated smoking devices, and other smoking requisites; and electrical and electronic equipment including electrodes, television systems, antennas, conductors or conductive bodies characterised by the conductive materials, and electrically stimulated smoking devices. The recorded exposure route is oral. Terazosin acts on seven protein targets. It selectively and competitively inhibits vascular postsynaptic alpha(1)-adrenergic receptors—specifically the alpha-1A (ADRA1A), alpha-1B (ADRA1B), and alpha-1D (ADRA1D) adrenergic receptors—which results in peripheral vasodilation and a reduction of vascular resistance and blood pressure. Unlike the nonselective alpha-adrenergic blockers phentolamine and phenoxybenzamine, terazosin does not block presynaptic alpha(2)-receptors and therefore does not cause reflex activation of norepinephrine release to produce reflex tachycardia. Additionally, it serves as an inducer of transforming growth factor beta-1 proprotein (TGFB1) and voltage-gated inwardly rectifying potassium channels KCNH2, KCNH6, and KCNH7.